« Previous
Next »
Titles
- Brand name drug prices increase more than twice as fast as inflation in 20181
- Brand name prescription drug prices increase four times faster than inflation in 20171
- Medicare spending trends 2010-2016: increase in prescription drug spending more than offsets lower beneficiary costs for other services1
- Price decreases for widely used generic drugs slow in 2017 after two years of substantial price drops1
- Prices for top Medicare Part D drugs have more than tripled since entering the market1
- Rx Price Watch report: retail prices for widely used brand name drugs increase considerably prior to generic competition1
- Rx Watchdog report: comparative measures of price change for prescription drugs and other goods1
- Rx price watch report: price growth for brand name and specialty drugs more than offset price decrease for generic drugs1
- Rx price watch report: specialty prescription drug prices continue to climb1
- Rx price watch report: trends in retail prices of brand name prescription drug widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of generic prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 20091
- Rx watchdog report trends in manufacturer prices of generic prescription drugs used by Medicare beneficiaries 2003 to 20071
- Rx watchdog report: brand name drug prices continue to climb despite low general inflation rate1
- Rx watchdog report: drug prices continue to climb despite lack of growth in general inflation rate1
- Rx watchdog report: trends in manufacturer prices of brand name prescription drugs used by Medicare beneficiaries 2002 to 20071
- Rx watchdog report: trends in manufacturer prices of prescription drugs used by Medicare beneficiaries, 2008 year-end update1
- Snapshots of recent state initiatives in Medicaid prescription drug cost control1
- Spending on individuals with type 1 diabetes and the role of rapidly increasing insulin prices1